The role of T cells in drug reaction

Current Allergy and Asthma Reports

Volumn 6, Issue 1, 2006, Pages 20-24

  Cavani, Andrea ^a   De Pità, Ornella ^b  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAMAZEPINE; CELECOXIB; DRUG; HYDROXYLAMINE; LAMOTRIGINE; LIDOCAINE; MEPIVACAINE; NITROSO DERIVATIVE; PENICILLIN G; SULFAMETHOXAZOLE;

ANTIGEN RECOGNITION; CELL ISOLATION; CLINICAL FEATURE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TOLERANCE; ERYTHEMA; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOTOXICITY; MACULOPAPULAR RASH; PATHOPHYSIOLOGY; PUSTULE; PUSTULOSIS; REVIEW; SKIN INFLAMMATION; STEVENS JOHNSON SYNDROME; SYSTEMIC DISEASE; T LYMPHOCYTE; TISSUE INJURY; TOXIC EPIDERMAL NECROLYSIS; VESICULAR RASH;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG HYPERSENSITIVITY; EXOCYTOSIS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 33645373021     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-006-0005-8     Document Type: Review

References (42)

1. Gruchalla RS: Drug allergy. J Allergy Clin Immunol 2003, 111:S548-S559.
2. Nierkens S, Pieters R: Murine models of drug hypersensitivity. Curr Opin Allergy Clin Immunol 2005, 5:331-335.
3. Baron JM, Merk HF: Drug metabolism in the skin. Curr Opin Allergy Clin Immunol 2001, 1:287-291.
4. Park BK, Naisbitt DJ, Gordon SF, et al.: Metabolic activation in drug allergies. Toxicology 2001, 158:11-23.
5. Pichler WJ: Delayed drug hypersensitivity reactions. Ann Intern Med 2003, 139:683-693.
6. Roujeau JC: Clinical heterogeneity of drug hypersensitivity. Toxicology 2005, 209:123-129.
7. Banchereau J, Briere F, Caux C, et al.: Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
8. Bajenoff M, Granjeaud S, Guerder S: The strategy of T cell antigen-presenting cell encounter in antigen-draining lymph nodes revealed by imaging of initial T cell activation. J Exp Med 2003, 198:715-724.
9. Moser M, Murphy KM: Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000, 1:199-205.
10. Farrar JD, Asnagli H, Murphy KM: T helper subset development: roles of instruction, selection, and transcription. J Clin Invest 2002, 109:431-435.
11. Davis SJ, Ikemizu S, Evans EJ, et al.: The nature of molecular recognition by T cells. Nat Immunol 2003, 4:217-224.
12. Weltzien HU, Moulon C, Martin S, et al.: T cell immune responses to haptens: structural models for allergic and autoimmune reactions. Toxicology 1996, 107:141-151.
13. Thierse HJ, Gamerdinger K, Junkes C, et al.: T cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens. Toxicology 2005, 209:101-107.
14. Padovan E, Mauri-Hellweg D, Pichler WJ, Weltzien HU: T cell recognition of penicillin G: structural features determining antigenic specificity. Eur J Immunol 1996, 26:42-48.
15. Pichler WJ: Direct T-cell stimulations by drugs - bypassing the innate immune system. Toxicology 2005, 209:95-100.
16. Engler OB, Strasser I, Naisbitt DJ, et al.: A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology 2004, 197:47-56.
17. Gallucci S, Matzinger P: Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13:114-119.
18. Mahnke K, Enk AH: Dendritic cells: key cells for the induction of regulatory T cells? Curr Top Microbiol Immunol 2005, 293:133-150.
19. Shevach EM: Regulatory/suppressor T cells in health and disease. Arthritis Rheum 2004, 50:2721-2724.
20. Cavani A, Nasorri F, Ottaviani C, et al.: Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol 2003, 171:5760-5768.
21. Cavani A, Nasorri F, Prezzi C, et al.: Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol 2000, 114:295-302.
22. Layland LE, Wulferink M, Dierkes S, Gleichmann E: Drug-induced autoantibody formation in mice: triggering by primed CD4+CD25- T cells, prevention by primed CD4+CD25+ T cells. Eur J Immunol 2004, 34:36-46.
23. Seguin B, Uetrecht J: The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003, 3:235-242.
24. Russell JH, Ley TJ: Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20:323-370.
25. Hildeman DA, Zhu Y, Mitchell TC, et al.: Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol 2002, 14:354-359.
26. Kuechler PC, Britschgi M, Schmid S, et al.: Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 2004, 59:613-622.
27. Traidl C, Merk HF, Cavani A, Hunzelmann N: New insights into the pathomechanisms of contact dermatitis by the use of transgenic mouse models. Skin Pharmacol Appl Skin Physiol 2000, 13:300-312.
28. Posadas SJ, Padial A, Torres MJ, et al.: Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002, 109:155-161.
29. Bronnimann M, Yawalkar N: Histopathology of drug-induced exanthems: Is there a role in diagnosis of drug allergy? Curr Opin Allergy Clin Immunol 2005, 5:317-321.
30. Yawalkar N, Hari Y, Frutig K, et al.: T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000, 115:647-652.
31. Schnyder B, Frutig K, Mauri-Hellweg D, et al.: T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998, 28:1412-1417.
32. Naisbitt DJ, Britschgi M, Wong G, et al.: Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003, 63:732-741.
33. Yawalkar N, Shrikhande M, Hari Y, et al.: Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000, 106:1171-1176.
34. Hertl M, Bohlen H, Jugert F, et al.: Predominance of epidermal CD8+ T lymphocytes in bullous cutaneous reactions caused by beta-lactam antibiotics. J Invest Dermatol 1993, 101:794-799.
35. Hertl M, Geisel J, Boecker C, Merk HF: Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993, 128:619-626.
36. Nassif A, Bensussan A, Dorothee G, et al.: Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002, 118:728-733.
37. Nassif A, Bensussan A, Boumsell L, et al.: Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004, 114:1209-1215.
38. Britschgi M, Steiner UC, Schmid S, et al.: T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001, 107:1433-1441.
39. Schmid S, Kuechler PC, Britschgi M, et al.: Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002, 161:2079-2086.
40. Schaerli P, Britschgi M, Keller M, et al.: Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol 2004, 173:2151-2158.
41. Mizukawa Y, Yamazaki Y, Teraki Y, et al.: Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol 2002, 161:1337-1347.
42. Teraki Y, Shiohara T: IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol 2003, 112:609-615.